Andrew Dunn is a senior biopharma correspondent at Endpoints News. He focuses on uncovering and explaining the future of the biotech and pharmaceutical industries, with particular interests in AI's role in biotech, cell and gene therapy, and the intersection of money and medicine. His work has been featured in prominent outlets including Yahoo News UK, Business Insider, and Forbes.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Charlotte, United States (Local)
Not enough data
Andrew Dunn's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly on biotech, pharmaceutical companies, and research & development. He also covers business and finance aspects related to these sectors.
Given his high percentage of press releases in his coverage attributes, Andrew might be more inclined towards news directly from companies within the healthcare and pharmaceutical industries. Therefore, he may be interested in pitches that provide exclusive insights into new drug developments, breakthrough technologies or significant funding announcements within these sectors.
As Andrew often writes about CEOs and investments in the industry, experts who can offer unique perspectives on leadership strategies within biotech/pharmaceutical companies or trends in R&D investment could grab his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Across the Network, affiliates are bringing different answers to those questions tailored to their states.
By: Andrew Dunn
Brent Saunders exits as Bausch + Lomb CEO by mutual agreement, replaced interim by Thomas Appio. Shares down 3%. Company to raise 2026 guidance.
State budgets remain dangerously dependent on Washington. Federal dollars account for 35% of the average state's revenue, according to the second
By: Andrew Dunn
Charlotte and Raleigh Republicans are accustomed to heading into Election Day with modest expectations. This year, Republicans across North Carolina may need to borrow some of that perspective.
The next chapter of state policy will soon begin, and likely with a new balance of power. November's elections will help determine what comes next for reforms that have expanded freedom and opportunity across the country.
By: Andrew Dunn
Senior Biopharma Correspondent In 2024, I started Endpoints News' flagship AI event because I didn't see anything like it.
By: Andrew Dunn
Whenever somebody in politics writes a book, the natural question is why. Are they running for president? Trying to repair their reputation?
By: Michelle Amponsah, Andrew Dunn
Get caught up.
With 58 candidates in 25 states, the Democratic Socialists of America is building legislative caucuses that could shape policy far beyond Congress
By: Andrew Dunn
Anthropic detailed AI biopharma efforts via Claude, working with Bristol Myers Squibb, BigHat, Enveda, Generate Biomedicines & The Column Group, while revealing its Mithril Medicine acquisition.
